← FDA DRUG APPROVALS

FDA ANDA · ANDA077324

LEVETIRACETAM

Sponsor: FOSUN PHARMA

APPLICATION
ANDA077324
TYPE
ANDA
ORIGINAL APPROVAL
2009-01-15
LATEST ACTION
2020-07-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LEVETIRACETAMDiscontinued
LEVETIRACETAM 750MG · TABLET · ORAL
LEVETIRACETAMDiscontinued
LEVETIRACETAM 250MG · TABLET · ORAL
LEVETIRACETAMDiscontinued
LEVETIRACETAM 1GM · TABLET · ORAL
LEVETIRACETAMDiscontinued
LEVETIRACETAM 500MG · TABLET · ORAL

Approval history

2020-07-24Manufacturing (CMC) · Supplement 8 · unknownAP
2014-09-24Labeling · Supplement 7 · standardAP
2010-12-29Labeling · Supplement 4AP
2010-11-22Labeling · Supplement 3AP
2010-03-15Labeling · Supplement 2AP
2009-04-15Labeling · Supplement 1AP
2009-01-15OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →